---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-066397"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:34:14.423972+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports Q1 net loss $84.6M; reiterates zidesamtinib pivotal data in H1 2025, NDA by mid-2025

## Summary
- Cash $1.1B at March 31, 2025; expected to fund operations into 2028.
- Q1 net loss $84.6M; R&D expense $74.4M, G&A expense $20.4M.
- Zidesamtinib pivotal data for TKI pre-treated ROS1+ NSCLC in H1 2025; NDA submission by mid-2025.
- Neladalkib pivotal data for TKI pre-treated ALK+ NSCLC by year-end 2025; ALKAZAR Phase 3 start in H1 2025.
- Leadership promotions: Ruth Adams to SVP Clinical Ops, Joshua Horan to SVP Chemistry, Jessie Lin to SVP Corporate Strategy.

## SEC filing metadata
- accession: 0000950170-25-066397
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000095017025066397/0000950170-25-066397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000095017025066397/nuvl-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-066397
- JSON: https://secwatch.observer/filing/0000950170-25-066397.json
- Plain text: https://secwatch.observer/filing/0000950170-25-066397.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.